Background: A number of practice guidelines incorporate the use of gene expression profiling (GEP) tests for early-stage, hormone receptor-positive, HER2-negative breast tumors. Few studies describe factors associated with GEP testing in US oncology practice. We assessed the relationship between clinical, demographic, and group-level socioeconomic variables and test use in women younger than 65 years. 35; 95% CI, 1.14-1.59), and higher out-of-pocket pharmacy costs (adjusted OR, 1.66; 95% CI, 1.40-1.97). Women younger than 50 years were more likely to be tested if they had stage I versus stage II disease (P<.0001).
Cancer, 3, [6] [7] [8] is a 21-gene assay that provides women and clinicians with a recurrence score (RS) result that, combined with other prognostic variables, can be used to identify women at either low, intermediate, or high risk of recurrence and estimate the benefit of adjuvant chemotherapy (to view the most recent version of the NCCN Guidelines, visit NCCN.org). [9] [10] [11] [12] [13] [14] [15] [16] Studies of GEP test adoption, and use of Oncotype DX specifically, suggest that between 20% and 50% of eligible women were tested. [17] [18] [19] [20] This rate of testing is likely aided by the incorporation of Oncotype DX testing into guidelines, 1,2 and the eventual attainment of nearly universal reimbursement by health plans for guideline-informed testing. 21, 22 These studies have found that, although rates of testing have increased 
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Background
A number a practice guidelines incorporate consideration of gene expression profiling (GEP) of early-stage, hormone receptor-positive, HER2-negative breast tumors with existing pathologic features to refine recurrence estimates and guide treatment recommendations. [1] [2] [3] [4] More limited evidence supports its use in patients with 1 to 3 positive nodes, 5 and testing is not included in clinical guidelines for these patients. The Oncotype DX Breast Cancer Assay (Genomic Health, Inc., Redwood City, CA), the most commonly used GEP test in the United States and, at the time of writing, the only GEP included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast since 2007, the year testing was first incorporated into a clinical practice guideline, the likelihood of testing varies across practice settings and is related to several clinical and demographic variables. Overall, rates of testing were highest among women with less-aggressive disease features and with estrogen and/or progesterone receptor (ER/PR)-positive, HER2-negative disease that reflects clinical practice guidelines for appropriate test use. Likewise, women with no or limited comorbidities were more likely to be tested, as were white versus African American women and those in their 50s (vs younger or older patients). 19, 20, 23 Previous studies of GEP test use are limited by small sample sizes, 20, 23 lack of representativeness of community practice, 19 or an inability to measure additional explanatory variables such as group-level economic variables or regional variation. Further, previous studies have focused on women of all ages. Given rates of testing are highest in women younger than 65 years, 19, 20, 23, 24 further attention is warranted to assess variables associated with testing in this population. The objectives of this study were to examine rates of GEP testing and to determine patient-level clinical, sociodemographic, and grouplevel socioeconomic variables associated with testing in an incident cohort of newly diagnosed women younger than 65 years with commercial health insurance. This study allowed us to assess test use in a large sample of newly diagnosed women receiving care across 5 states.
Patients and Methods
Patient Selection and Study Cohort
Details of data linkages are presented in supplemental eAppendix 1 (available with this article at JNCCN. org). Briefly, our linked database consists of 5 state cancer registries containing clinical and pathologic variables linked with claims data maintained by HealthCore Inc. (Wilmington, DE), an independent subsidiary to Anthem, Inc., an independent licensee of the Blue Cross and Blue Shield Association. We linked RS results through collaboration with Genomic Health, the patent holder of the Oncotype DX test. A total of 16,064 women between ages 24 and 64 years diagnosed with breast cancer (according to tumor registry data) and successfully linked with HealthCore claims were assessed for eligibility based on Anthem coverage policies for Oncotype DX testing. These coverage policies were consistent with NCCN Guidelines for Breast Cancer 3 during the study period. We selected only those women diagnosed with a first invasive breast cancer (n=14,710). Based on guidelines for GEP testing, we excluded women with in situ disease, or stage III or IV or with missing stage (n=2728). We also excluded women with both ER and PR missing, both ER-and PR-negative, or at least one negative/ borderline and the other missing (n=2538). These exclusions resulted in a final cohort of 9,444 women diagnosed through April 30, 2012 , who may have been considered for GEP testing. The participating registries, HealthCore, and Georgetown obtained all necessary IRB and HIPAA approvals for this linkage.
Study Measures
Receipt of GEP testing was identified by a linkage between HealthCore and Genomic Health test data for Anthem-covered members with breast cancer whose GEP testing was performed by Genomic Health. From registry data we obtained age at diagnosis, race/ethnicity, marital status, year of diagnosis, and diagnosis of prior primary cancers other than breast cancer, including nonmelanoma skin cancers. Staging was created using the AJCC classification for staging of breast cancer (7th edition), which is based on the TNM system. 25 We obtained ER, PR, HER2, and nodal status and histologic grade from registry data. We grouped women as having either ER-and PR-positive tumors or those having either PR-or ER-positive tumors (but not both). Women with a borderline HER2 status and those with an "unknown" status were compared with those with a HER2-negative status. HER2 status was derived using the SEER Collaborative Stage Site-Specific Factor 15 (positive/negative/borderline/unknown). Furthermore, those with N0 disease were compared with those with N1mic and N1 disease. Well-and moderately differentiated tumors were compared with poorly differentiated or undifferentiated tumors. From HealthCore's Integrated Research Database (HIRD), 26 we ascertained 31 individual health comorbid conditions diagnosed in women from 1 year before their breast cancer diagnosis up to and including the month of diagnosis based on the Elixhauser comorbidity index. 27 For each condition, we used a commonly applied algorithm that required an inpatient diagnosis and/or at least 2 outpatient diagnosis codes at least 30 days apart to minimize false-positives. HIRD also contains information on copays, deductibles, and coinsurance for services provided that were used to create an out-of-pocket pharmacy payment burden variable (in quintiles) over the previous 6 months before the breast cancer diagnosis. Finally, members' residential 5-digit zip codes were linked to derive sociodemographic data based on the US Census Bureau 2007-2011 American Community Survey, including median household income (in quintiles) and urban versus rural location.
Statistical Analysis
We examined the bivariate relationship between the receipt of testing and each variable. We included all variables in a multivariable logistic regression model with GEP test receipt as a binary dependent variable and all other variables as main effects. Before running our final multivariable model, we tested several hypothesized interactions individually when added to the main effects model ({age} × {year tested, stage, comorbidity}; {out of pocket pharmacy costs} × {year tested, stage, comorbidity}; {year tested} × {stage}). We only report those interaction terms that met our criteria for statistical significance (type I error of 0.05) in the final multivariable model. All tests were 2-sided, and we used a type I error of 0.05. Because of the high number of cases with unknown HER2 status, we performed sensitivity analyses, including only those with known HER2 status (n=4980) and among those with node-negative (N0; n=7054) versus node-positive (N1mic/N1; n=2390) disease and among eligible patients for GEP testing according to practice guidelines (n=6546). We report adjusted odds ratios (ORs) and 95% CI produced by the logistic regressions. All calculations were performed using SAS 9.3 (Cary, NC).
Results
In this cohort, 2371 women (25.1%) received GEP testing ( Table 1 ). The 9444 women with early-stage, hormone receptor-positive disease were evenly divided across years of diagnosis, were primarily white, were previously unaffected with cancer, had no comorbidity, and resided in urban areas. Although most tested patients had breast cancers whose clinical features aligned with clinical practice guidelines, with an overall 31.4% rate of testing across all years, 9.0% of tested women (n=213) did not meet these guidelines.
Testing increased significantly over time (P<.0001; Figure 1 (Figure 2) .
The overall effect for race/ethnicity was significant (P<.0001), with non-Hispanic black women the only group to be significantly less likely to be tested than non-Hispanic white women (OR, 0.61; 95% CI, 0.45-0.82). Women with at least one comorbid condition before their cancer diagnosis were more likely to be tested than those with no comorbidities (OR, 1.35; 95% CI, 1.14-1.59; P=.0006). There was significant regional variation, with Georgia having the highest adjusted percentages of testing, and California (OR, 0.63; 95% CI, 0.53-0.76) and Kentucky (OR, 0.77; 95% CI, 0.62-0.97) having the lowest testing rates. Rural patients also were less likely to be tested than urban patients (OR, 0.74; 95% CI, 0.57-0.95; P=.0206). Testing was higher among those in the top 3 quartiles of out-of-pocket pharmacy costs (OR, 1.22; 95% CI, 1.02-1.45; OR, 1.52; 95% CI, 1.29-1.80; and OR, 1.66; 95% CI, 1.40-1.97, respectively) compared with those in the lowest quintile.
Results of sensitivity analyses were similar to our primary model, with a few minor exceptions, mostly resulting in a loss of statistical significance for variables due to loss of sample size in our sensitivity analyses (supplemental eAppendix 2, available with this article on JNCCN.org).
Discussion
To our knowledge, this is the largest and most representative study of US oncology practice among treated women younger than 65 years to investigate the use of Oncotype DX testing. We found that multiple clinical, demographic, and group-level economic variables are associated with the likelihood of testing in women younger than 65 years with early-stage breast cancer.
Testing rates among women with node-negative disease nearly doubled in the first few years after clinical practice guidelines incorporated GEP testing, increasing to 35% among women with N0, hormone receptor-positive, HER2-negative disease. This is a lower rate than reflected in marketing data publicly reported by Genomic Health in 2015, which suggest that testing of guideline-eligible women of all ages has continued to increase after 2011. 28 Rates of testing among women with node-positive disease also increased as the evidence base for this practice began to develop, and with the opening of the RxPONDER trial (SWOG S1007; ClinicalTrials.gov identifier: NCT01272037), which examines the effectiveness of chemohormonal versus hormonal therapy alone for women with 1 to 3 positive nodes. 29, 30 Nonetheless, rates of testing remain lower for this group. Overall, time trends in test use appear to be influenced by factors such as the evidence for clinical utility, coverage by insurers, and incorporation into clinical practice guidelines. 31 Future changes in adoption are likely after the results of ongoing trials and other validation studies are published, and in response to increases in patient demand for testing. Qualitative studies with oncologists suggest that they take a number of factors into consideration when ordering testing, including not only clinical variables but also patients' pretest preferences for chemotherapy 32 and the degree of uncertainty regarding their recommendation for chemotherapy. 33 Additional multimethod research is needed to further understand oncologists' decision-making processes regarding the use of GEP testing, and precision medicine more broadly, and how they involve patients in this process.
The likelihood of testing was strongly associated with clinical criteria that align with clinical practice guidelines. A minority of tested patients had disease features that made them ineligible for testing according to guidelines consistent with Anthem's policies for testing during our study period. However, some oncologists could have determined that testing of N1 women outside of the guidelines would add value based on the current literature, 5 pending the results of the RxPONDER clinical trial. 29 It also is possible that these patients were discovered to have positive nodes subsequent to GEP testing. 34 We also found that a small number of women with HER2-positive disease were tested outside clinical practice guidelines.
Our findings for age by stage suggest that oncologists are more likely to test younger women if they have stage I versus stage II disease. Although we found similar, nonsignificant trends for older patients, this pattern of care could reflect how oncologists use patient variables to determine the clinical utility of testing for individual patients, and therefore, whether they should order testing. For example, the presence of more aggressive stage II disease in younger women and their higher tolerance for chemotherapy-related side effects could lead oncologists to determine that chemotherapy is the optimal treatment for these patients, regardless of their RS. 35, 36 Additionally, in the studies that established the clinical utility of the Oncotype DX test and led to its incorporation in clinical practice guidelines, less than 10% of the women were younger than 40 years. 13, 37 Oncologists may therefore be generally less inclined to test patients younger than 40 years and those presenting with stage II disease, because of the potential benefit offered by chemotherapy regardless of test result.
Conversely, they could be more open to omitting chemotherapy for stage I disease. 32 Our results also suggest that the likelihood of testing in our cohort was higher among patients with at least one preexisting comorbidity. These results differ from those of previous studies that have uniformly found that rates of testing are inversely related to the presence of comorbidites. 19, 24 This difference may be due to our younger cohort, because greater comorbidity may be associated with less benefit from chemotherapy, and increases the probability of adverse toxicity events from chemotherapy. 38 Although GEP testing and chemotherapy may be less likely to be considered for women older than 65 years, in our cohort, the positive association of testing with comorbidity may reflect the use of the test to help identify the subgroup of women at a higher risk of chemotherapy-induced toxicity and reductions in quality of life who might safely forgo chemotherapy. 39 Although our sample was large, we were limited in the inclusion of African American, Asian American/Pacific Islander, and Hispanic participants. Despite this small subsample, our results replicated several studies that found lower rates of testing among non-Hispanic black women. 19, 20, 23 The consistency of this finding suggests that this may represent an emerging but unexplained disparity in the use of genomic medicine among women with breast cancer that requires further investigation. Although we did not have information on care settings, such as whether patients were treated in an academic or community setting, all patients in our sample were covered by commercial insurance and, therefore, should have somewhat comparable access. We adjusted for outof-pocket pharmaceutical payment burden to help mitigate possible variability in access within our covered population. Further, we believe that this is the first study to document regional variation in the ordering of GEP testing, and lower rates of testing among rural versus urban patients. Although these effects were diminished in sensitivity analyses among women with confirmed HER2 status, regional variations in other unrelated aspects of cancer care and outcomes are well documented. [40] [41] [42] Regional variation in GEP testing could reflect continued clinical uncertainty or professional disagreements among oncologists regarding the utility of GEP testing.
Finally, we found that testing rates were higher for patients with greater out-of-pocket burden for pharmacy costs. Although we are uncertain about the specific reasons for these differences, we speculate that this finding may be partly the result of oncologists' efforts to protect patients with a higher cost-sharing burden from the cost of chemotherapy if it will not significantly lower their risk for recurrence. Overall, our results suggest that oncologists consider not only disease characteristics but also additional nonclinical factors that appear to affect who receives GEP. There is room for an additional increase of testing among patients who are otherwise eligible per clinical practice guidelines. Our study is limited by the high proportion of patients with unknown HER2 status. We were unable to account for certain variables possibly related to test use, such as academic centers versus community centers, the specialty of the oncologist ordering the GEP test, and unmeasured patient-level variables. Finally, our study may have limited generalizability to all community practice. Our cohort includes women younger than 65 years with commercial health insurance in 5 US states. Our results reflect regional variation that might not reflect use in the US overall.
Conclusions
To our knowledge, this is the largest populationbased study to assess use of GEP testing in US oncology practice. We found that the use of testing increased substantially after inclusion in clinical practice guidelines. Our results suggest that there are many eligible patients who are not tested. Although it appears that oncologists have incorporated testing for selected patients, rates of Abbreviations: ER, estrogen receptor; GEP, gene expression profiling; OR, odds ratio; PR, progesterone receptor. Figure 2 Interaction between age and stage among tested women.
Adjusted odds of being tested was significantly higher for stage I versus stage II disease among women diagnosed at younger than 50 years. There were no significant differences in test use by stage in women aged 50 years and older.
Abbreviations: ER, estrogen receptor; GEP, gene expression profiling; OR, odds ratio; PR, progesterone receptor. 
